Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. Pre-clinical testing of a microcontrol...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/16/4123 |
id |
doaj-ff1ac6cf968846c59e41530251643439 |
---|---|
record_format |
Article |
spelling |
doaj-ff1ac6cf968846c59e415302516434392021-08-26T13:35:53ZengMDPI AGCancers2072-66942021-08-01134123412310.3390/cancers13164123Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in GlioblastomaCarolin Golla0Mayas Bilal1Annika Dwucet2Nicolas Bader3Jenson Anthonymuthu4Tim Heiland5Maximilian Pruss6Mike-Andrew Westhoff7Markus David Siegelin8Felix Capanni9Christian Rainer Wirtz10Richard Eric Kast11Marc-Eric Halatsch12Georg Karpel-Massler13Department of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Mechatronics and Medical Engineering, Ulm University of Applied Sciences, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Pediatric and Adolescent Medicine, Ulm University Medical Center, 89075 Ulm, GermanyDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USADepartment of Mechatronics and Medical Engineering, Ulm University of Applied Sciences, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyIIAIG Study Center, Burlington, VT 05408, USADepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyThe purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. Pre-clinical testing of a microcontroller-based device emitting light of 405 nm wavelength in combination with exposure to 5-ALA (PDT) and the Bcl-2/Bcl-xL inhibitor ABT-263 (navitoclax) was performed in human established and primary cultured glioblastoma cells as well as glioma stem-like cells. We applied cell count analyses to assess cellular proliferation and Annexin V/PI staining to examine pro-apoptotic effects. Western blot analyses and specific knockdown experiments using siRNA were used to examine molecular mechanisms of action. Bcl-2/Bcl-xL inhibition synergistically enhanced apoptosis in combination with PDT. This effect was caspase-dependent. On the molecular level, PDT caused an increased Noxa/Mcl-1 ratio, which was even more pronounced when combined with ABT-263 in a Usp9X-independent manner. Our data showed that Bcl-2/Bcl-xL inhibition increases the response of glioblastoma cells toward photodynamic therapy. This effect can be partly attributed to cytotoxicity and is likely related to a pro-apoptotic shift because of an increased Noxa/Mcl-1 ratio. The results of this study warrant further investigation.https://www.mdpi.com/2072-6694/13/16/4123glioblastoma5-aminolevulinic acidphotodynamic therapyABT-263navitoclaxBcl-xL |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carolin Golla Mayas Bilal Annika Dwucet Nicolas Bader Jenson Anthonymuthu Tim Heiland Maximilian Pruss Mike-Andrew Westhoff Markus David Siegelin Felix Capanni Christian Rainer Wirtz Richard Eric Kast Marc-Eric Halatsch Georg Karpel-Massler |
spellingShingle |
Carolin Golla Mayas Bilal Annika Dwucet Nicolas Bader Jenson Anthonymuthu Tim Heiland Maximilian Pruss Mike-Andrew Westhoff Markus David Siegelin Felix Capanni Christian Rainer Wirtz Richard Eric Kast Marc-Eric Halatsch Georg Karpel-Massler Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma Cancers glioblastoma 5-aminolevulinic acid photodynamic therapy ABT-263 navitoclax Bcl-xL |
author_facet |
Carolin Golla Mayas Bilal Annika Dwucet Nicolas Bader Jenson Anthonymuthu Tim Heiland Maximilian Pruss Mike-Andrew Westhoff Markus David Siegelin Felix Capanni Christian Rainer Wirtz Richard Eric Kast Marc-Eric Halatsch Georg Karpel-Massler |
author_sort |
Carolin Golla |
title |
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma |
title_short |
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma |
title_full |
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma |
title_fullStr |
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma |
title_full_unstemmed |
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma |
title_sort |
photodynamic therapy combined with bcl-2/bcl-xl inhibition increases the noxa/mcl-1 ratio independent of usp9x and synergistically enhances apoptosis in glioblastoma |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-08-01 |
description |
The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. Pre-clinical testing of a microcontroller-based device emitting light of 405 nm wavelength in combination with exposure to 5-ALA (PDT) and the Bcl-2/Bcl-xL inhibitor ABT-263 (navitoclax) was performed in human established and primary cultured glioblastoma cells as well as glioma stem-like cells. We applied cell count analyses to assess cellular proliferation and Annexin V/PI staining to examine pro-apoptotic effects. Western blot analyses and specific knockdown experiments using siRNA were used to examine molecular mechanisms of action. Bcl-2/Bcl-xL inhibition synergistically enhanced apoptosis in combination with PDT. This effect was caspase-dependent. On the molecular level, PDT caused an increased Noxa/Mcl-1 ratio, which was even more pronounced when combined with ABT-263 in a Usp9X-independent manner. Our data showed that Bcl-2/Bcl-xL inhibition increases the response of glioblastoma cells toward photodynamic therapy. This effect can be partly attributed to cytotoxicity and is likely related to a pro-apoptotic shift because of an increased Noxa/Mcl-1 ratio. The results of this study warrant further investigation. |
topic |
glioblastoma 5-aminolevulinic acid photodynamic therapy ABT-263 navitoclax Bcl-xL |
url |
https://www.mdpi.com/2072-6694/13/16/4123 |
work_keys_str_mv |
AT carolingolla photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT mayasbilal photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT annikadwucet photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT nicolasbader photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT jensonanthonymuthu photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT timheiland photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT maximilianpruss photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT mikeandrewwesthoff photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT markusdavidsiegelin photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT felixcapanni photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT christianrainerwirtz photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT richarderickast photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT marcerichalatsch photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma AT georgkarpelmassler photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma |
_version_ |
1721194549079965696 |